Clinical trials: Glial Tumors
Glioma, Neurofibromatosis Type 1
MicroRNAs in Patients With Neurofibromatosis Type 1
MicroRNAs are small molecules which have recently been discovered in cells. They are known to be responsible for the normal development of cells and when they are disrupted can contribute to the development of cancer.
- Trial name
- NCT01595139
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Glioblastoma (GBM), Newly Diagnosed Glioblastoma Multiforme
A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma
This is a phase I clinical trial evaluating the safety, tolerability, and maximum tolerated dose of MSC11FCD, an investigational allogeneic bone marrow-derived mesenchymal stem cell therapy expressing a suicide gene, in patients…
- Trial name
- NCT07143812
- Testing
- MSC11FCD
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- CHA University
Brain and Central Nervous System Tumors
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00482677
- Testing
- temozolomide, DNA methylation analysis, quality-of-life assessment
- Where
- 22 sites in Canada, Germany and 2 more
- Volunteers
- 562 people
- Sponsor
- Canadian Cancer Trials Group
Glioblastoma Multiforme, Cognition Disorders
Bevacizumab and Lomustine for Recurrent GBM
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Glioblastoma Multiforme, Cognition Disorders, Disability Evaluation
- Trial name
- NCT01290939
- Testing
- bevacizumab, lomustine, DNA methylation analysis
- Where
- 2 sites in Netherlands
- Volunteers
- 592 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238277
- Testing
- temozolomide, adjuvant therapy, chemotherapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
High Grade Glioma, MGMT-Unmethylated Glioblastoma
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients.
- Conditions
- High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
- Trial name
- NCT06504381
- Testing
- DB107-RRV, DB107-FC, Radiation Therapy (RT)
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
First Progression of Glioblastoma
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Despite comprehensive multimodal treatment of newly diagnosed glioblastoma, almost all patients suffer from tumour relapse. Currently, no standard of care exists to treat these tumour relapses.
- Trial name
- LEGATO (NCT05904119)
- Testing
- Lomustine, Reirradiation
- Where
- 45 sites in Austria, Belgium and 9 more
- Volunteers
- 411 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent or Progressive Malignant Glioma
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma.
- Trial name
- NCT00539344
- Testing
- ANG1005
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Angiochem Inc
Glioblastoma (GBM)
Effect of stRess and exeRcize on the Outcome After Chemo-Radiation
Glioblastoma (GBM) is a highly malignant, incurable primary brain tumor. Due to the nature of this disease and the extent of the treatment (surgery followed by chemoradiation according to the Stupp trial) patients undergo…
- Trial name
- ERROR (NCT05431348)
- Testing
- Smartwatch, Serum Cortisol, Questionnaires
- Where
- 2 sites in Netherlands
- Volunteers
- 42 people
- Sponsor
- Maastricht Radiation Oncology
Glioma, Recurrent High Grade, Grade 4 Malignant Glioma
A Study of NST-628 in Recurrent Grade 4 Glioma
This is an open-label, single arm, non-randomized, Phase 0 and expansion Phase 1 study of NST-628 in adult patients with recurrent Grade 4 glioma with high phosphorylated extracellular signal-regulated kinase (pERK) expression…
- Trial name
- NCT07784985
- Testing
- NST-628
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nader Sanai
Glioma, Brain Metastases, Adult
Revision of the EORTC QLQ-BN20 Questionnaire
Despite the fact that use of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Brain Neoplasm (QLQ-BN20) has tremendously contributed to insight into the health-related quality…
- Trial name
- QLQBN20 (NCT04689321)
- Testing
- No intervention
- Where
- Netherlands
- Volunteers
- 135 people
- Sponsor
- Leiden University Medical Center
Glioblastoma (GBM)
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
The objective of this study is to evaluate the safety, feasibility, and preliminary antitumor activity of this multi-component immunotherapy strategy in patients with advanced solid tumors.
- Trial name
- NCT07762716
- Testing
- BreakVax, Ipilimumab 2.5 mg, Pembrolizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- BreakBio Corp
Brain Cancer
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
The goal of this clinical research study is to find a safe dose of radiation that can be given to patients with brainstem glioma who have already received radiation therapy. You will receive photon radiation therapy.
- Trial name
- NCT01469247
- Testing
- Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma
- Trial name
- NCT03919071
- Testing
- Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture
- Where
- 131 sites in United States, Puerto Rico
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Glioblastoma
Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma
Glioblastoma is recognized as the most common and aggressive form of primary malignant brain tumor, with treatment options that are limited and prognosis that is extremely poor, showing median progression-free survival of 12…
- Trial name
- NCT06368934
- Testing
- sub-lobectomy, imaging total resection
- Where
- China
- Volunteers
- 326 people
- Sponsor
- Huashan Hospital
Glioma, Glioblastoma Multiforme
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma.
- Trial name
- NCT06011109
- Testing
- APG-157
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Aveta Biomics, Inc.
Glioblastoma
Glioblastoma Targeted Treatment Option Maximization by WGS
In Dutch centers performing neurosurgery on and/or treating GBM, all recurrent GBM patients are discussed in local tumor boards and this setup will be used to effectively identify possible GLOW study candidates.
- Trial name
- GLOW (NCT05186064)
- Testing
- whole genome sequencing
- Where
- Netherlands
- Volunteers
- 164 people
- Sponsor
- UMC Utrecht
Glioma
Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application
Individual overexpression of the three miRNAs negatively affects cell viability and proliferation mainly in grade III IDH-wild type cells, while in higher grade cells, the effect is more pronounced when the entire signature is…
- Trial name
- NCT06883214
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Regina Elena Cancer Institute
Glioblastoma
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma
- Trial name
- NCT02770378
- Testing
- Temozolomide, Aprepitant, Minocycline
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University of Ulm
Solid Tumor, Hepatocellular Carcinoma
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
- Conditions
- Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, Glioma
- Trial name
- NCT04550663
- Testing
- KD-025 CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.